Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma
- PMID: 20150383
- PMCID: PMC2940570
- DOI: 10.1093/neuonc/nop019
Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma
Abstract
The purpose of this study is to determine prognostic factors in patients with high-grade recurrent glioma for 3 outcome variables (overall survival, progression-free survival [PFS], and PFS rate 6 months after study registration [PFS6]). Data from 15 North Central Cancer Treatment Group (NCCTG) trials (n = 469, 1980-2004) and 12 North American Brain Tumor Consortium (NABTC) trials (n = 596, 1998-2002) were included. Eighteen prognostic variables were considered including type of treatment center (community/academic) and initial low-grade histology (yes/no). Recursive partitioning analysis (RPA), Cox proportional hazards, and logistic regression models with bootstrap resampling were used to identify prognostic variables. Longer survival was associated with last known grade (Grade) of III, younger age, ECOG performance score (PS) of 0, shorter time from initial diagnosis (DxTime), and no baseline steroid use. Factors associated with longer PFS were Grade III and shorter DxTime. For patients without temozolomide as part of the treatment regimen, the only factor associated with better PFS6 was Grade III, although DxTime was important in RPA and PS was important in logistic regression. Grade was the most important prognostic factor for all three endpoints regardless of the statistical method used. Other important variables for one or more endpoints included age, PS, and DxTime. Neither type of treatment center nor initial low-grade histology was identified as a major predictor for any endpoint.
Similar articles
-
Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials.J Clin Oncol. 2007 Jun 20;25(18):2601-6. doi: 10.1200/JCO.2006.08.1661. J Clin Oncol. 2007. PMID: 17577040 Free PMC article.
-
The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.Dan Med J. 2014 Oct;61(10):B4944. Dan Med J. 2014. PMID: 25283629
-
Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy.BMC Cancer. 2009 Dec 18;9:450. doi: 10.1186/1471-2407-9-450. BMC Cancer. 2009. PMID: 20017960 Free PMC article.
-
Factors influencing survival in high-grade gliomas.Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4. doi: 10.1053/j.seminoncol.2003.11.031. Semin Oncol. 2003. PMID: 14765378 Review.
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840 Review.
Cited by
-
The prognostic role of intragenic copy number breakpoints and identification of novel fusion genes in paediatric high grade glioma.Acta Neuropathol Commun. 2014 Feb 18;2:23. doi: 10.1186/2051-5960-2-23. Acta Neuropathol Commun. 2014. PMID: 24548782 Free PMC article.
-
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.Neuro Oncol. 2011 May;13(5):509-16. doi: 10.1093/neuonc/nor017. Epub 2011 Mar 3. Neuro Oncol. 2011. PMID: 21377994 Free PMC article. Clinical Trial.
-
Viral vector: potential therapeutic for glioblastoma multiforme.Cancer Gene Ther. 2020 May;27(5):270-279. doi: 10.1038/s41417-019-0124-8. Epub 2019 Jul 18. Cancer Gene Ther. 2020. PMID: 31316136 Review.
-
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).Neuro Oncol. 2020 May 15;22(5):705-717. doi: 10.1093/neuonc/noz232. Neuro Oncol. 2020. PMID: 31844890 Free PMC article. Clinical Trial.
-
Prognostic significance of systemic inflammatory parameters in high-grade glial tumor patients: Two center experience.Medicine (Baltimore). 2024 Apr 19;103(16):e37726. doi: 10.1097/MD.0000000000037726. Medicine (Baltimore). 2024. PMID: 38640334 Free PMC article.
References
-
- Wong ET, Kenneth RH, Gleason MJ, et al. Outcome and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572–2578. - PubMed
-
- Breiman L, Friedman RA, Stone CJ. Classification and Regression Trees. Belmont, CA: Wadsworth; 1983.
-
- Therneau TM, Atkinson EJ. Rochester, MN: Department of Health Science Research, Mayo Clinic; 1997. Technical Report Series No. 61. An introduction to recursive partitioning using the RPART routines.
-
- Wiencke JK, Aldape K, McMillan A, et al. Molecular features of adult glioma associated with patient race/ethnicity, age and a polymorphism in O6-methlyguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev. 2005;14:1774–1783. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical